Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease …
$7.73+1.71%
报价 2026-11-06
市值
$31.2M
EV
$36M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -38.7%
$5.19$12.60
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
market cap below $300M floor
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RMTIRockwell Medical, Inc. | $31.2M | +1.7% | +4.3% | 17.7% | – | – | 21.2x | |
| CPIXCumberland Pharmaceuticals Inc. | $78.2M | +4.2% | -14.9% | 83.4% | – | – | – | |
| TLPHTalphera, Inc. | $54.5M | +4.0% | +29430.6% | -4,075% | – | – | – | |
| ATHEAlterity Therapeutics Limited | $41.2M | +9.5% | – | 0% | – | – | – | |
| STRRStar Equity Holdings, Inc. | $33.6M | -4.0% | +35.4% | 43% | – | – | – | |
| EVAXEvaxion Biotech A/S | $18.9M | +8.7% | – | 100% | – | – | – | |
| QNTMQuantum BioPharma Ltd. | $13.5M | -0.2% | – | 0% | – | – | – | |
| NMTCNeuroOne Medical Technologies Corporation | $8M | +2.1% | +33.9% | 55.7% | – | – | – | |
| APUSApimeds Pharmaceuticals US, Inc | $4.1M | -0.9% | – | 0% | – | – | – | |
| 同行中位数 | – | – | +34.7% | 21.5% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。